Press "Enter" to skip to content

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.

Original source:

Also Read:   FDA Publishes List of Essential Medicines, Medical Countermeasures, Critical Inputs Required by Executive Order